Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies
Abstract The natural serotypes of adeno-associated virus (AAV) or their variants, such as AAV8 and AAV5, are commonly used as vectors in the clinical programs for liver-targeted gene therapy. While AAV8 vectors are not highly efficient at targeting primary human hepatocytes, AAV3 vectors have recent...
Main Authors: | Mika Ito, Naomi Takino, Takamasa Nomura, Akihiko Kan, Shin-ichi Muramatsu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-04-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-88614-9 |
Similar Items
-
Systemic Delivery of Tyrosine-Mutant AAV Vectors Results in Robust Transduction of Neurons in Adult Mice
by: Asako Iida, et al.
Published: (2013-01-01) -
Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
by: Pengfei Li, et al.
Published: (2019-01-01) -
Thermostability of Adeno-Associated Virus (AAV) Vectors
by: Pacouret, Simon
Published: (2018) -
Adeno-Associated Viral Vectors in Neuroscience Research
by: David L. Haggerty, et al.
Published: (2020-06-01) -
Adeno‐associated virus‐vectored influenza vaccine elicits neutralizing and Fcγ receptor‐activating antibodies
by: Daniel E Demminger, et al.
Published: (2020-05-01)